Skip to main content

SR One Capital Management, LP

13F filer · CIK 0001910264
Reported Aug 12, 2026
Net seller this quarter
13F portfolio value$1.04BU.S. long equity reported on 13F
Positions153 new · 2 closed
Net flow last quarter-$103MBuys minus sells
Top 10 positions weight95.1%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 12, 202615 positions
MANEVeradermics, Inc$295M28.42%5.75%Not reportedQ1 2026
ZBIOZenas BioPharma, Inc.$128M12.31%7.95%Not reportedQ3 2024
CRSPCRISPR Therapeutics AG$111M10.70%2.11%Not reportedQ1 2024
AVLNAvalyn Pharma Inc.$109M10.48%7.46%NewQ2 2026
DSGNDesign Therapeutics, Inc.$94.4M9.09%10.43%Not reportedQ4 2021
ODTXOdyssey Therapeutics, Inc.$71M6.83%7.92%NewQ2 2026
ALMSAlumis Inc.$55.2M5.31%Not reportedNot reportedQ2 2024
ORICOric Pharmaceuticals, Inc.$50M4.81%4.45%+2.2%Q2 2025
MLYSMineralys Therapeutics, Inc.$42.2M4.06%1.77%Not reportedQ1 2023
SPRYARS Pharmaceuticals, Inc.$32.1M3.09%4.04%Not reportedQ4 2022
MOBIMobia Medical, Inc.$26.6M2.56%5.97%NewQ2 2026
NKTXNkarta, Inc.$9.43M0.91%4.66%Not reportedQ2 2022
OCSOculis Holding AG$8.89M0.86%Not reportedNot reportedQ1 2025
RAREUltragenyx Pharmaceutical Inc.$4.6M0.44%0.14%Not reportedQ4 2025
ENGNenGene Therapeutics Inc.$1.29M0.12%1.12%Not reportedQ2 2024
Q1 2026Reported May 14, 202614 positions
ACLXArcellx, Inc.$269M29.43%4.01%Not reportedQ1 2022
MANEVeradermics, Inc$152M16.57%6.43%NewQ1 2026
ZBIOZenas BioPharma, Inc.$98.5M10.76%8.08%Not reportedQ3 2024
CRSPCRISPR Therapeutics AG$97M10.59%2.12%Not reportedQ1 2024
DSGNDesign Therapeutics, Inc.$69.4M7.59%10.45%Not reportedQ4 2021
ORICOric Pharmaceuticals, Inc.$58.5M6.39%4.36%Not reportedQ2 2025
ALMSAlumis Inc.$43.2M4.72%Not reportedNot reportedQ2 2024
MLYSMineralys Therapeutics, Inc.$42.4M4.63%1.90%Not reportedQ1 2023
SPRYARS Pharmaceuticals, Inc.$32.2M3.52%4.04%Not reportedQ4 2022
ORKAOruka Therapeutics, Inc.$21.1M2.31%0.86%Not reportedQ3 2024
OCSOculis Holding AG$17M1.86%Not reportedNot reportedQ1 2025
NKTXNkarta, Inc.$7.03M0.77%4.68%Not reportedQ2 2022
ENGNenGene Therapeutics Inc.$5.09M0.56%1.12%Not reportedQ2 2024
RAREUltragenyx Pharmaceutical Inc.$2.89M0.32%0.14%Not reportedQ4 2025
Q4 2025Reported Feb 12, 202613 positions
ZBIOZenas BioPharma, Inc.$183M25.90%9.25%+2.6%Q3 2024
ACLXArcellx, Inc.$153M21.66%4.05%Not reportedQ1 2022
CRSPCRISPR Therapeutics AG$107M15.14%2.13%Not reportedQ1 2024
DSGNDesign Therapeutics, Inc.$61.2M8.67%10.81%Not reportedQ4 2021
MLYSMineralys Therapeutics, Inc.$56.8M8.03%1.92%-26.0%Q1 2023
SPRYARS Pharmaceuticals, Inc.$46.8M6.62%4.04%Not reportedQ4 2022
ORICOric Pharmaceuticals, Inc.$37.8M5.34%4.58%Not reportedQ2 2025
ALMSAlumis Inc.$19.1M2.71%Not reportedNot reportedQ2 2024
ORKAOruka Therapeutics, Inc.$13M1.85%0.88%Not reportedQ3 2024
OCSOculis Holding AG$12.8M1.81%Not reported+98.8%Q1 2025
ENGNenGene Therapeutics Inc.$6.75M0.96%1.12%Not reportedQ2 2024
NKTXNkarta, Inc.$6.17M0.87%4.69%Not reportedQ2 2022
RAREUltragenyx Pharmaceutical Inc.$3.17M0.45%0.14%NewQ4 2025
Q3 2025Reported Nov 12, 202512 positions
ACLXArcellx, Inc.$193M27.86%4.06%Not reportedQ1 2022
CRSPCRISPR Therapeutics AG$132M19.11%2.17%+94.4%Q1 2024
ZBIOZenas BioPharma, Inc.$109M15.77%11.64%Not reportedQ3 2024
MLYSMineralys Therapeutics, Inc.$80.2M11.59%2.68%-32.4%Q1 2023
ORICOric Pharmaceuticals, Inc.$54.2M7.84%4.64%Not reportedQ2 2025
DSGNDesign Therapeutics, Inc.$49.1M7.11%11.46%Not reportedQ4 2021
SPRYARS Pharmaceuticals, Inc.$40.3M5.83%4.06%Not reportedQ4 2022
ORKAOruka Therapeutics, Inc.$8.28M1.20%0.89%Not reportedQ3 2024
ALMSAlumis Inc.$7.82M1.13%Not reportedNot reportedQ2 2024
NKTXNkarta, Inc.$6.9M1.00%4.69%Not reportedQ2 2022
OCSOculis Holding AG$5.67M0.82%Not reportedNot reportedQ1 2025
ENGNenGene Therapeutics Inc.$5.11M0.74%1.46%Not reportedQ2 2024
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.